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esponsibility of InstAbstract Discovered by Youyou Tu, one of the 2015 Nobel Prize winners in Physiology or Medicine,
together with many other Chinese scientists, artemisinin, artemether and artesunate, as well as other
artemisinins, have brought the global anti-malarial treatment to a new era, saving millions of lives all
around the world for the past 40 years. The discoveries of artemisinins were carried out beginning from
the 1970s, a special period in China, by hundreds of scientists all together under the “whole nation”
system. This article focusing on medicinal chemistry research, brieﬂy introduced the discovery and
invention course of the scientists according to the published papers, and highlighted their academic
contribution and achievements.
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1.1. Discovery of new anti-malarials in a whole nation system
During the Vietnam–US War in the early 1960s, Vietnamese soldiers
suffered from serious malaria because a mutated form of Plasmodium
falciparum wreaked havoc in Vietnam. Under the request from North
Vietnamese government to provide effective drugs against multidrug-
resistant malaria, China started, on May 23, 1967, a project to search
for new antimalaria drugs; the project, named “Project 523”, was
managed under the “whole nation” system, and it involved sixty
research organizations and more than 500 scientists1,2. All activities of
the project were directed by the entity known as “Project 523”.
1.2. The program for new drugs or lead compounds from
traditional Chinese medicine (TCM) and folk medicine
One of the various programs in the “Project 523” was a team for the
“study and survey on effective folk medicine and therapy against
malaria”. Making every endeavor, the team obtained several hits,
including a sesquiterpene, yingzhaosu A, from Artabotrys hexapetalus,
a metal-containing principle in the plant Polyalthiane moralis, analogs
of β-dichroine and components from Artemisia3.
1.3. The discovery of artemisia and artemisinin
In 1969, the Institute of Chinese Materia Medica (ICMM), China
Academy of Traditional Chinese Medicine, joined the “Group of
TCM” of Project 523. Youyou Tu of ICMM was the group leader.
She and her ICMM colleague Yagang Yu and Guoming Gu of
Academy of Military Medical Sciences (AMMS), collected and
screened more than 100 simple and compound recipes from well-
recorded folk medicines and TCM, where they found that
Artemisia appeared in high frequency for recorded efﬁcacy against
malaria (anti-malarial action of Artemisia was recorded in many
ancient Chinese herb books in Dynasties Tang, Song, Yuan and
Ming). Through systematic bioassay-guided screening by Yu and
Gu, an alcoholic extract of Artemisia was discovered to exert
inhibitory activity against Plasmodium falciparum by up to
60%–80%1. The extent of the inhibition was unfortunately highly
variable; however, the results from Yu and Gu provided valuable
references for further investigations.
Critical progress was subsequently made by Youyou Tu, who
was inspired by the detailed methods of Artemisia usage described
in ancient Ge Hong’s book “Zhou Hou Bei Ji Fang”. The book
reads: for the treatment of malaria “a handful of Artemisia soaked
in two liter of water. Take the pressed juice.” She deduced that the
disuse of decoction (by boiling) may imply thermo-instability of
active principles, which nonetheless may be lipophilic. Therefore,
she switched from ethanol to ether as the extraction solvent. After
removing the acidic principles, white solids were isolated from the
neutral ethereal extraction, which exerted 100% inhibition against
mouse P. falciparum. The white solids were later identiﬁed to be
artemisinin (1) (Fig. 1). The discovery of artemisinin from the
ethereal extraction certainly played a critical role in opening new
therapeutic means and saving millions of lives from malaria
illness. It also justiﬁes Youyou Tu’s sharing of the 2015 Nobel
Prize for Physiology or Medicine.
In addition to artemisinin, several other sesquiterpenes were
identiﬁed from the ethereal extraction, including arteannuic acid
(2), arteannuin A (3), arteannuin B (4), arteannuin C (5), andamorphane (6) (Fig. 1). However, these compounds all exerted
weak or no anti-malaria activity4.2. Structural identiﬁcation of artemisinin
2.1. Physicochemical properties
Artemisinin is white needle-like crystals with mp 151–153 1C.
Elementary analysis and mass spectra showed the molecular formula
of C15H22O5. It is insoluble in water, but dissolves in acetone,
ethanol, ether, petroleum ether and alkali solution. NaOH titration of
artemisinin consumes one equivalent. Qualitative analyses give
positive color reactions in the oxidation of FeCl2 or NaI. It
quantitatively reacts with triphenylphosphine to give one equivalent
of triphenylphosphine oxide. These reactions indicated the existence
of an oxidative group in its molecule.
2.2. Spectral behavior
The ultraviolet spectra (UV) of artemisinin showed the absence of
an aromatic conjugate system. The infrared spectra (IR) indicated
carbonyl peak of δ-lactone. 13C NMR revealed the presence of
ﬁfteen carbon signals, the numbers of primary, secondary, tertiary
and quaternary carbon being 3, 4, 5 and 3, respectively. For the
quaternary carbons, one yielded a carbonyl signal, whereas the
other two were at low ﬁeld (79.5 and 105 ppm)，indicating
linkage to an oxygen atom. Five doublet signals of tertiary carbon
atoms appeared at the high ﬁeld. 1H NMR showed a singlet at
5.68 ppm, indicating the presence of an –O–CH–O– fragment.
Based on the biogenesis of sesquiterpene, the 4 oxygen atoms
were deduced as ketal, acetal and lactone moieties in the
artemisinin scaffold. Yet the 5th oxygen was not deﬁned.
At that time (1975), Dequan Yu, a member of the TCM group of
Project 523 at the Institute of Materia Medica, CAMS, promulgated
the chemical structure of another anti-malarial natural product,
yingzhaosu A，which contains a peroxy linkage5. This information
conferred an enormous enlightenment for solving the artemisinin
structure. Based on the oxidation of artemisinin in qualitative and
quantitative analyses, a peroxy moiety was designated in the structure,
at three possible locations, as shown in 1, 7 and 8 (Figs. 1 and 2).
The location of the peroxy linkage and the structure of
artemisinin were authentically deﬁned by the method of X-ray
crystallography in the Institute of Biophysics, Chinese Academy
of Scince (CAS). The absolute conﬁguration was determined by
optical rotatory dispersion (ORD)6–8.
2.3. Chemical reactions of artemisinin—evidence in support of
structure
Hydrogenation of artemisinin, under the catalyst of Pd/CaCO3,
gave rise to a product, coined reduced artemisinin, with the peroxy
moiety being reduced into ether linkage. The structure of reduced
artemisinin is identical to that of arteannuin C (5). The mechanism
of the reduction is illustrated in Scheme 1.
Artemisinin reacts with NaBH4 under low temperature to produce
dihydroartemisinin (9, Scheme 2), in which the C10-carbonyl group
is reduced into hydroxyl in the form of hemi-acetal. In the presence
of Lewis acid with the treatment with NaBH4 the C10-carbonyl
group of artemisinin converts into methylene group (10, Scheme 2);
artemisinin reacts with acetic-sulfuric acid to generate (11), where the
Figure 2 Chemical structures of compound 7 and 8 with a peroxy
moiety.
Figure 1 Chemical structures of sesquiterpenes identiﬁed from the
ethereal extraction of Artemisia.
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acid, as shown in Scheme 2.2.4. Total synthesis of artemisinin—validation of structure
The success in total synthesis of artemisinin in China was
accomplished by Xingxiang Xu and co-workers in Shanghai
Institute of Organic Chemistry, CAS. Based upon biogenic
principle of artemisinin, it was believed that arteannuic acid (2),
in abundant content in the plant, may be the precursor for the
biosynthesis of artemisinin. So a synthetic scheme was designed
and performed as concisely illustrated in Scheme 3. Esteriﬁcation
of arteannuic acid (2) gives 2a, which is treated with NaBH4 to
saturate the exo-double bond to give 2b. Opening the octahydro-
naphthalene through ozonization creates the monocyclic keto-
aldehyde 2c. Selective protection of the ketone group by 1,3-
dimercaptopropane gives 2d, which is treated with orthoformate to
modify the aldehyde group, giving rise to 2e. Removal of the
protecting sulfoether group produces 2f, which is converted to the
key intermediate 2g by the oxygen–photooxidation reaction.
Acidolysis of 2g is automatically followed by cascade reactions
to form the peroxy, ether and lactone-containing compound
artemisinin (1)9.
Simultaneously, Schmid and Hofheinz10 using a different route
completed the total synthesis of 1. Several synthetic strategies and
improvements were subsequently reported. The success in total
synthesis of artemisinin provided authentic evidence for the
artemisinin structure (Fig. 3), and also paved the way for its
industrial production.2.5. Preliminary clinic trails
After conducting the safety experiments in animals and healthy
volunteers with neutral components of ethereal extraction, Tu’s group
proceeded to clinic therapy in Beijing and Hainan Province, China. A
deﬁnite therapeutic efﬁcacy was demonstrated in the treatment of 30
patients with various types of malaria. The neutral component mainly
contains artemisinin (at that time called Artemisinin II). Tu’s work both
on the discovery of artemisinin and the proof of its action unequivocally
created a new area of malaria treatment.
2.6. The large-scale production of artemisinin and validation of
clinic efﬁcacy
Inspired by the success of the ethereal extraction method and the
preliminary clinical effect, Zeyuan Luo (member of Project 523 in
Yunnan Institute of Material Medica) and Zhenxing Wei (member
of Project 523 in Shandong Institute of Chinese Traditional
Medicine) obtained artemisinin in pure quality from the local
plant Artemisia annua L. Especially, Luo’s invention of “Petro-
solvent extraction” laid the material foundation for the large scale
production of artemisinin and subsequent clinical trials.
Cooperating with Luo, who provided pure artemisinin, Guoqiao
Li (member of Project 523 at Guangzhou Institute of Chinese
Traditional Medicine) conducted clinical trails for malaria patients
in Yunnan Province. Artemisinin (originally called Huang Hao Su)
was orally administered to patients. Li showed that the ﬁne
ring forms of P. falciparum in human body ceased development
and their abundance rapidly decreased, indicating that the efﬁcacy
of artemisinin was far superior to those of quinine and chlor-
oquine. Following oral administration of artemisinin, 18 patients
suffering different forms of malaria were totally cured, including
cerebral falciparum (1 case), P. falciparum jaundice type (2 cases),
uncomplicated falciparum (11 cases) and vivax malaria (4 cases).
Li’s clinical research was the ﬁrst to show artemisinin to be an
effective, fast-acting, and low-adverse-effect antimalarial medi-
cine. His work conveyed an important contribution to the clinical
application of artemisinins11.3. Lead optimization—modiﬁcation of artemisinin
As a special sesquiterpene, artemisinin contains ﬁve interweaving
oxygen atoms to form cyclic ether and peroxy ether, cyclic acetal
and ketal, as well as lactone. Given the absence of a solubilizing
moiety in its structure, artemisinin is insoluble in water, and poorly
soluble in lipids. The poor biopharmaceutic properties and low
bioavailability of artemisinin restricts its clinical application, even
though artemisinin was approved and launched by China Food and
Drugs Administration (CFDA) in 1985. In order to develop
artemisinin-related drugs, the “Project 523” took on further
optimization of the lead compound. Because of lack of knowledge
on the mechanism of action by artemisinin, phenotype evaluation
and analysis of structure–activity relationships were also per-
formed in the optimization process.
3.1. Critical structural features—peroxy linkage and special
scaffold
The change in peroxy moiety of artemisinin into ether linkage
results in reduced artemisinin (5), which is devoid of anti-malarial
Scheme 1 The generation mechanism of reduced artemisinin.
Scheme 2 Acid-catalytic decarbonylation and rearrangement.
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yingzhaosu A, it was inferred that the peroxy moiety is one of the
pharmacophoric features. However, other peroxy-containing com-
pounds with different skeletons did not exert the anti-malarial
activity, suggesting that the speciﬁc scaffold of artemisinin is also
one of the critical factors. Therefore, these two features were kept
constant in the further optimization and the design of derivatives.
3.2. Artemisinin-related drug in China—artemether
The ﬁrst important derivative dihydroartemisinin (9) was obtained
for identifying artemisinin structure. Compound 9 exerted stronger
activities than did the lead compound 1, a result suggesting that
alterations in the lactone moiety retains or raises the activity. In
order to further increase the anti-malarial activity and chemical
stability, Ying Li and co-workers synthesized additional deriva-
tives with two types of functional groups: ethers and esters.
3.2.1. C10-ethereal compounds
Under the catalysis of BF3-ether, dihydroartemisinin (9) reacts
with various alcohols to yield acetal-ethers (general structure 12,Fig. 4). The products consist of two diastereomers (α- and β-
epimers; β-epimer predominates), which are both stable com-
pounds. The separated ethereal α and β-monomers were evaluated
against chloroquine-resistant mouse P. berghei (compared to
artemisinin as the control), for a determination of the dose for
inhibition of 90% Plasmodium (SD90). The structure and activity
of typical ethereal compounds are listed in Table 1. The data show
that the activity of dihydroartemisinin (9) is one time stronger than
that of artemisinin (1). The methyl ether (13) increases the activity
two times compared to 9. However, with increase in the size of
alkyl group the activities decrease. Generally β-epimers show
higher activity than corresponding α-epimers. β-C10-O-methyl
dihydroartemisinin (β-13, also named as artemether) was the
strongest congener in the ethereal series.
3.2.2. C10-ester compounds
Dihydroartemisinin (9) reacts with anhydrides, acyl chlorides, or
chloroformates in pyridine medium to yield C10-carboxy esters or
carbonate esters (general structure 22, Fig. 5) 12,13.The structures
and activities of these esters against P. berghei are listed in
Table 2. The activity of ester compounds in general are stronger
Scheme 3 Synthetic route of artemisinin starting from arteannuic acid (2).
Figure 3 The location of the peroxy linkage and the structure of
artemisinin deﬁned by the method of X-ray crystallography and the
absolute conﬁguration determined by optical rotatory dispersion
(ORD).
Figure 4 General chemical structures of acetal-ethers.
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follows: carbonates4carboxy esters4ethers4dihydroartemisi-
nin4artemisinin.
Additionally, Yu and co-workers synthesized C10-substituted
benzoates of dihydroartemisinin. The biological results indicated
that the halogen- and nitro-containing molecules were similar to
artemisinin in activity14,15, except compound 32 (Fig. 6), whose
activity is 10 times stronger than artemisinin.3.2.3. Bis-ethereal dihydroartemisinin
Using polymethylene as a linkage to connect two dihydroartemi-
sinin, Chen and co-workers16 synthesized a series of bis-ethereal
dihydroartemisinins (general structure 33, Fig. 6) that had C10,100-
α, β or β, β conﬁgurations. However, the biological evaluation
showed that none of them was more active than compound 13
(artemether).3.2.4. The QSAR of dihydroartemisinin derivatives
Multiple regression analysis was performed for the ester and ether
derivatives of dihydroartemisinin using Hansch analysis method,
correlating antimalarial activities to the linear free-energy related
descriptors. The signiﬁcant equations are as follows17:
for ester and ether derivatives:
log 1=C¼ 1:155 logP–0:198 logPð Þ2–0:612I þ 1:120
n¼ 49; r ¼ 0:911; s¼ 0:153; log Popt ¼ 2:91 ð1Þ
for ester derivatives:log 1=C¼ 0:872 logP–0:159 logPð Þ2–0:360I þ 1:625
n¼ 30; r¼ 0:923; s¼ 0:130; logPopt ¼ 2:74 ð2Þ
for ether derivatives:
log 1=C¼ 1:162 logP–0:223 logPð Þ2–0:145I–0:637σn þ 0:958
n¼ 14; r¼ 0:905; s¼ 0:168; log Popt ¼ 2:60 ð3Þ
In the equations, C is the molar concentration of a congener for
inhibiting 90% growth in P. berhgei; P is the partition coefﬁcient
determined in the system of n-octanol and water; indicator variable I
is assigned the value of 1 for congeners of C10 β-epimers and zero
for α-epimers; and σ* means Taft electronic substituent constant.
As Eqs. (1) and (2) indicate, the variance in antimalarial activities of
dihydroartemisinin ester and ether series is well explained by the
parabolic logP, and the optimal partition coefﬁcients for maximum
activities (2.6–2.9) are consistent with those in the other antimalarial
compounds. More potent activity in α-epimers than in the corresponding
β-epimers is indicated by the minus coefﬁcient of indicator variable
I [α : β ¼ antilog (0.612 : 0) ¼ 4.2 : 1]. For the ester series the
correlation Eq. (2) is the same as Eq. (1), although the coefﬁcients are
different. In the series of ethers, however, an additional term (electronic
parameter σ*) had to be added to make the correlation signiﬁcant. This
suggests the mode of action and/or transport process of the ether series
be different from those of the ester derivatives.
3.2.5. Artemether—one of the candidates selected for drug
development
Three compounds with high antimalarial activity were selected
from the above-described dihydroartemisinin ethers, carboxylic
Table 1 The anti-malarial activity against P. berghei of
ethereal compounds of dihydroartemisinin.
Figure 5 General chemical structures of C10-esters compounds.
Table 2 The anti-malarial activity against P. berghei of
carboxylic ester and carbonate compounds of dihydroartemisinin.
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experimental therapy against P. berhgei in mice. The results for
compounds 13 (β-epimer, artemether), 24 (α-epimer of propio-
nate), and 29 (α-epimer of ethoxycarbonate) are listed in Table 3.
Data show that the 3 compounds possess favorable therapeutic
effects for infected mice. Furthermore, the therapeutic efﬁcacy of
these compounds for P. berhgei-infected cynomolgus monkeys
was demonstrated (data not shown)18. After comparing the three
compounds for the toxicities in mice, rats, rabbits, dogs, and
monkeys, as well as the physic–chemical properties, artemether
(13, β-epimer) was chosen as the candidate to start with for further
pre-clinical investigations18. In 1978, the clinical trials com-
menced. In 1987, artemether was approved by CFDA as a new
molecule entity and launched in various formulations.3.2.6. Another candidate selected for drug development —
artesunate
To develop water-soluble artemisinin-related drugs for injection
formulations, Xu Liu of Guilin Pharmaceutical Company designed
and synthesized dihydroartemisinin C10-monoesters of diacids.
One of the compounds is succinic acid monoester (34, Code No.804, Fig. 6), the structure of which was deﬁned by IR, NMR, MS,
and X-ray crystallography. The sodium salt of 34 is soluble in
water and suitable for injection dosage19,20.
Preclinical investigations indicate that compound 34 (coined as
artesunate) exerts strong antimalarial effects. In mouse malaria, the
activity against chloroquine-resistant and -sensitive strains was
respectively 5.2 and 5.3 times greater than that of artemisinin (1)
when sodium artesunate was given intravenously. In monkey
malaria, the time required for disappearance of plasmodia from the
blood stream was 16–20 h when artesunate was administered
intravenously at a dosage of 6–12 mg/kg q.d. for three days.
Sub-acute toxicity experiments on rabbits and dogs given i.v.
sodium artesunate showed no harmful effects on cardiac, hepatic
and renal functions at test dosage, nor were any apparent structural
changes found upon pathological examination21.
Pharmacokinetic experiments in animals showed that artesunate
was rapidly distributed and hydrolyzed to dihydroartemisinin. The
plasma half-life (t1/2) was 15.6 min in rats and 10–45 min in dogs.
After oral administration in volunteers, the bioavailability of artesunate
was 40% and t1/2 was 41.35 min
22. Clinical trials indicated that
artesunate exerts signiﬁcant therapeutic effect for the treatment of
patients with tertian falciparum and cerebral malaria. Artesunate was
approved by CFDA in 1987 as a new molecule entity and launched in
various formulations.3.2.7. Compound formulations—the combination artemisinin-
related drugs with other anti-malarials
In spite of the high efﬁciency and fast-action advantages against all
kinds of malaria, artemether and artesunate still suffer from a
common drawback. With very short half-lives, artemrther and
artesunate are so quickly cleared from plasma that the plasmodia
of patients cannot be completely removed. Furthermore, as drug
resistance develops to existing drugs, new ones need to be
introduced. For P. falciparum, the use of two or more drugs with
different modes of action in combination is now recommended, to
provide adequate cure rate and delay development of resistance.
Figure 6 Chemical structures of compound 32–38.
Table 3 The comparison of antimalarial activity of com-













13 (Artemether) 0.60 1.00 1.22 1.80
24 (Propionate) – 0.50 0.47 0.82
29 (Ethoxycarbonate) 0.32 0.66 0.76 0.91
1 (Artemisinin) – 6.2 – 25
9 (Dihydroartemisinin) – 3.7 – –
aThe dose required for 50% suppression of the parasitemia.
bThe dose required for 90% suppression of the parasitemia.
cMouse, p.o., once daily, after 5 days the minimum dose required
for 50% negative conversion of the parasitemia.
dMouse, p.o., once daily, after 5 days the minimum dose required
for 100% negative conversion of the parasitemia.
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mended for the treatment of P. falciparum malaria. Fast acting
artemisinin-based compounds are combined with a drug from a
different class. Compound formulations have been developed
for artemether, artesunate and dihydroartemisinin, as described
below.
(1) Compound artemether tablet is the ﬁrst ﬁxed-dose artemisi-
nin-based combination formulation, which contains arte-
mether (13) and lumefantrine (35, Fig. 6). Lumefantrine was
synthesized and developed as a new anti-malarial drug by
Rongxian Deng and coworkers23 in 1981. The compound
artemether tablet was designed by Rongxian Deng and Dingxi
Ning and then recommended and pre-qualiﬁed by World
Health Organization (WHO) for the treatment of uncompli-
cated malaria caused by P. falciparum. It has been shown to
be effective for multi-drug resistant P. falciparum and
recommended as ﬁrst-line treatment for uncomplicated
malaria in several countries. In 1992, the tablet formulationwas approved in China under the trade name Coartems; each
tablet contains artemether 20 mg, lumefantrine 120 mg. In
2002 Coartems was included in the 12th edition of the
“Essential drug list” by WHO. In 2009, the FDA approved
Coartems in the USA.
(2) Artesunate (34) /amodiaquine (36, Fig. 6), another dose-ﬁxed
tablet formulation, was launched in 2007, under the trade
name Coarsucum. Each tablet contains artesunate 100 mg and
amodiaquine 270 mg. In 2007 it was pre-qualiﬁed in the
therapeutic list by WHO.
(3) Dihydroartemisinin (9) /piperaquine (37, Fig. 6) is a clinically
investigated ACT tablet under the trade name Artekins. Each
tablet contains dihydroartemisinin 40 mg and piperaquine
320 mg24.3.3. The mechanism of action of artemisinin-related drugs
Most artemisinin-related drugs in use today are prodrugs, which are
activated through hydrolysis to the metabolite dihydroartemisinin.
Several lines of evidence indicate that artemisinin drugs exert their
anti-malarial action by radical formation via their peroxide linkage.
During the stage when the parasite is located inside red blood cells, it
consumes hemoglobin within its digestive vacuole by the hemoglobin
degradation enzyme. The process releases ferrous ions, which catalyze
the cleavage of the peroxy moiety to form oxygen or carbon free
radicals. These free radical intermediates disrupt the biomembrane and
inhibit the cysteine protease of the vacuoles. Scheme 4 illustrates the
reaction process catalyzed by ferrous ions via two proposed pathways.
The products are marked by the boxes25.
Another plausible mechanism of action for artemisinin drugs
consists of the inhibition of the target “P. ferghei calcium ATP
protein 6” (PfATP6). PfATP6 is a SERCA-type protein enzyme,
which modulates the calcium concentration within P. plasma
through consumption of ATP to maintain calcium homeostasis.
Inhibition of PfATP6 by artemisinins causes the increase of
calcium levels within P. plasma and kills P. Heritability studies
suggest that the observed artemisinin resistance phenotype of the
parasites has a genetic basis—the mutation of PfATP626,27.
Scheme 4 The products and biochemical mechanism of artemisinins' action.
Table 4 The structure, physico-chemical properties, and antimalarial activitya of compounds 39–46.






P. yoelii ED90 (mg/kg) P. yoelii artesunate
index
sc po sc po sc po sc
Artesunate 565 2.77 7.2 7.1 1.0 1.0 22.0 – 1.0
39 8 5.62 0.8 3.5 9.0 2.0 0.85 3.0 25.9
40 o 2 4.78 0.6 2.8 12 2.5 0.52 2.0 42.3
41 89 2.49 1.5 3.1 4.8 2.3 3.9 5.0 5.6
42 o 1 5.59 1.16 5.0 6.2 1.4 1.08 – 20.4
43 o 1 6.15 3.8 4.6 1.9 1.7 3.0 – 7.3
Artesunatec 565 2.77 4.6 9.3 1.0 1.0 42.0 – 1.0
44 28.4 3.05 0.18 1.3 25.6 7.15 1.25 1.84 33.6
45 o 2 4.97 0.51 1.9 9.0 4.9 0.61 2.0 81.0
Artesunatec 565 2.77 12.0 – 1.0 – 50.0 – 1.0
46 1251 2.63 9.0 – 1.3 – 10.0 – 5.0
Artemisinin 63 2.94 – – – – – – –
Artemether 117 3.98 – – – – – – –
aIn vivo screens against CQ-sensitive P. berghei N strain and CQ-resistant P. yoelii NS strain. Peters' four-day test with mice treated daily
subcutaneously (sc) or orally (po) from the day of infection (Day 0) through Day 3; results (ED90 values) were based on parasite counts in peripheral
blood on day 4.
bED90 (artesunate) / ED90 (tested compound).
cThe variation in artesunate activity in different experiments.
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4.1. Arteether
Arteether (38, artemotil, Fig. 6)，or dihydroartemisinin-C10-β-ethy-
lether，was developed by Brocacef Co.28 in Netherlands and launched
in 2000. Arteether is used as a sesame oil formulation for intramuscular
injection to treat patients with falciparum malaria. At 3–12 h after
injection, it reaches peak plasma concentration; plasma half-life (t1/2)
was 1–2 days. Oxidative deethylation of arteether by liver CYP3A4
occurs to form dihydroartemisinin, which is glycosylated by glucuronic
acid, leading to be clearance from bile. As a follow-on medicine,
arteether does not show any advantage over artemether.
4.2. Artemisone
Bayer and Hong Kong University of Science & Technology set up a
project with the aim to improve artemisinin pharmacokinetics.
Artemether, arteether, and artesunate are rapidly hydrolyzed in plasma
to dihydroartemisinin, which is conjugated to glucuronic acid and
excreted from bile, events that cause these drugs’ short duration of
action. Moreover, dihydroartemisinin exerts some neurotoxicity. To
prolong time period of action and avoid the production of dihydroar-
temisinin, a series of compounds were synthesized. Some notable
compounds (39–46) and their physico-chemical properties, as well as
anti-malarial activity, are listed in Table 429. The data show that
compounds 39, 40, 42, 44 and 45 exert strong activities. However, in
rat primary neuronal brain stem cell culture tests, these compounds
showed toxicities. Compounds 42 and 43 at the dose of 50mg/kg/day,
caused substantial body-weight loss, coupled with reduced motility,
uncoordinated gait, and piloerection. Compound 41, which has
excellent physic–chemical and pharmacological properties, was vali-
dated to be a safe and effective antimalarial in aotus monkeys; the
compound, named artemisone, is now in phase II clinical trial.5. Concluding remarks
The discovery of artemisinin and the development of a series of
related drugs in China have pioneered a new era for the treatment
of malaria. These drugs have served as the standard regimen for
treating P. falciparum and saved millions of malarial patients
worldwide. The tremendous successes of the artemisinin anti-
malarial therapy were due to the serendipitous discovery by
Youyou Tu and the efforts of the organizers and other participants
of “the 523 Project”, including many scientists/technologists,
covering the ﬁelds of chemistry, pharmacognosy, medicinal
chemistry, pharmacology, toxicology, pharmaceutics and proces-
sing, as well as clinical and industrial partners. Today this type of
“whole-nation” R&D program, which was a product of the unique
historical period that encompassed the “Cultural Revolution” and a
period that suffered signiﬁcant economic hardship and paucity of
modern infrastructure for drug development, will unlikely be
mimicked or reproduced. Furthermore, this particular case is also
ﬂawed by the lack of intellectual property protection and the low
share of market proﬁt by the inventors. However, as a signiﬁcant
contribution to human health, the R&D program of artemisinins
deserves the ultimate recognition by the society, as symbolized by
the Noble Prize.
Scientiﬁcally, with the unique structure of the artemisinins, there
remains an enormous space for further investigations. Extensive efforts
have to be devoted to the elucidation of drug targets and mechanismsof action, the improvement of pharmacokinetic properties, and the
identiﬁcation of a novel generation of artemisinins against resistant
strains of plasmodia. In addition, the promiscuity of artemisinin has
also provided clues for the search for drugs in other therapeutic
ﬁelds30–32.References
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